Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VIII. The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics
Abstract
<p>The reviews in this special edition have presented a primer on the state of the literature for six different psychedelic compounds and their plausible role in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader healthcare landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly-acting treatments. It is crucial to note this is an emerging field of medicine, and only one of these compounds (esketamine) is currently FDA-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.</p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.